Peter E. Anastasiou
President bei ALDER BIOPHARMACEUTICALS, INC.
Vermögen: - $ am 31.03.2024
Profil
Peter E.
Anastasiou is currently the Chief Executive Officer & Director at Capsida Biotherapeutics, Inc., Director at Pharmaceutical Research & Manufacturers of America, and Independent Director at Harmony Biosciences Holdings, Inc. He was previously the President at Lundbeck Seattle BioPharmaceuticals, Inc. Before that, he held positions such as Marketing Director at Bristol Myers Squibb Co., Principal at Eli Lilly & Co., Executive Vice President-North America at H.
Lundbeck A, and Vice President-Marketing at Neuronetics,.
Inc. Anastasiou received his undergraduate degree from Albion College and his MBA from Kelley School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.11.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Peter E. Anastasiou
| Unternehmen | Position | Beginn |
|---|---|---|
| ALDER BIOPHARMACEUTICALS, INC. | President | - |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Director/Board Member | 05.11.2023 |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Director/Board Member | 01.07.2017 |
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Chief Executive Officer | 01.01.2022 |
Ehemalige bekannte Positionen von Peter E. Anastasiou
| Unternehmen | Position | Ende |
|---|---|---|
| H. LUNDBECK A/S | Corporate Officer/Principal | 31.12.2021 |
| BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| NEURONETICS, INC. | Sales & Marketing | - |
Ausbildung von Peter E. Anastasiou
| Albion College | Undergraduate Degree |
| Kelley School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| H. LUNDBECK A/S | Health Technology |
| NEURONETICS, INC. | Health Technology |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Seattle BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Its product includes Eptinezumab, is an investigational monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA. | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Capsida Biotherapeutics, Inc. engages in the development of gene therapies for life threatening genetic disorders. It focuses on the provision of adeno-associated virus engineering platform to generate targeted gene therapies. The company is headquartered in Westlake Village, CA. | Commercial Services |
